Allergan has acquired Topokine Therapeutics, a clinical-stage biotechnology company focused on topical medicines for fat reduction, for $85 million upfront and success-based development and sales milestones for XAF5, a topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.
 
XAF5 penetrates the skin and acts pharmacologically on fat cells to shrink undereye bags. In XOPH5-OINT-2, a Phase II randomized, placebo-controlled clinical trial, XAF5 met the primary endpoint achieving statistically significant and clinically meaningful reductions in undereye bags. In January 2016 Topokine initiated XOPH5-OINT-3, a pivotal Phase IIb/III study of XAF5.
 
“The acquisition of Topokine and its XAF5 technology adds an innovative technology to Allergan’s industry leading mid-to-late stage pipeline of more than 70 programs and bolsters our leadership in medical aesthetics,” said David Nicholson, executive vice president and president, Global Brands R&D at Allergan. “XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients. We look forward to continuing the outstanding development work conducted by the Topokine team to bring this innovative medical aesthetic treatment to market.”